FR14C0069I2 - Composition pharmaceutique comprenant le lurasidone - Google Patents

Composition pharmaceutique comprenant le lurasidone

Info

Publication number: FR14C0069I2
Authority: FR; France
Prior art keywords: lurasidone; pharmaceutical composition; pharmaceutical; composition
Prior art date: 2005-05-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR14C0069C

Other languages

English (en)

French (fr)

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sumitomo Pharma Co Ltd

Original Assignee

Sumitomo Dainippon Pharma Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-26

Filing date

2014-09-16

Publication date

2015-11-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452103&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR14C0069(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-09-16 Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd

2014-10-24 Publication of FR14C0069I1 publication Critical patent/FR14C0069I1/fr

2015-11-20 Application granted granted Critical

2015-11-20 Publication of FR14C0069I2 publication Critical patent/FR14C0069I2/fr

Status Active legal-status Critical Current

Links

PQXKDMSYBGKCJA-CVTJIBDQSA-N lurasidone Chemical compound C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 PQXKDMSYBGKCJA-CVTJIBDQSA-N 0.000 title 1
229960001432 lurasidone Drugs 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Inorganic Chemistry (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychiatry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Neurosurgery (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

FR14C0069C 2005-05-26 2014-09-16 Composition pharmaceutique comprenant le lurasidone Active FR14C0069I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2005153508		2005-05-26
PCT/JP2006/310571 WO2006126681A1 (ja)	2005-05-26	2006-05-26	医薬品組成物

Publications (2)

Publication Number	Publication Date
FR14C0069I1 FR14C0069I1 (fr)	2014-10-24
FR14C0069I2 true FR14C0069I2 (fr)	2015-11-20

Family

ID=37452103

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR14C0069C Active FR14C0069I2 (fr)	2005-05-26	2014-09-16	Composition pharmaceutique comprenant le lurasidone

Country Status (22)

Country	Link
US (5)	US8729085B2 (de)
EP (2)	EP2422783B1 (de)
JP (2)	JP4733120B2 (de)
KR (2)	KR101552033B1 (de)
CN (2)	CN102048734B (de)
AU (1)	AU2006250340C1 (de)
BR (2)	BRPI0611409B8 (de)
CA (1)	CA2606510C (de)
CY (2)	CY1114118T1 (de)
DK (2)	DK1884242T3 (de)
ES (2)	ES2408687T3 (de)
FR (1)	FR14C0069I2 (de)
HK (1)	HK1108379A1 (de)
HU (1)	HUS1400051I1 (de)
LU (1)	LU92550I2 (de)
MX (1)	MX2007014872A (de)
NL (1)	NL300690I2 (de)
PL (1)	PL1884242T3 (de)
PT (1)	PT1884242E (de)
RU (1)	RU2398586C3 (de)
SI (1)	SI1884242T1 (de)
WO (1)	WO2006126681A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1886678B1 (de) *	2005-05-18	2017-04-19	Sumitomo Dainippon Pharma Co., Ltd.	Stabile tablette mit droxidopa
BRPI0611409B8 (pt) *	2005-05-26	2021-05-25	Dainippon Sumitomo Pharma Co	preparação oral compreendendo lurasidona
JP5401327B2 (ja) *	2008-02-11	2014-01-29	大日本住友製薬株式会社	溶出性の改善された錠剤
KR101618388B1 (ko)	2008-06-13	2016-05-04	다이닛본 스미토모 세이야꾸 가부시끼가이샤	구강 내 급속 붕해 정제 및 이의 제조 방법
CN102170912A (zh) *	2008-09-30	2011-08-31	大洋药品工业株式会社	压缩成型制剂及其制造方法
WO2010135396A2 (en)	2009-05-19	2010-11-25	Celgene Corporation	Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
CA2814840C (en)	2010-10-18	2018-08-28	Dainippon Sumitomo Pharma Co., Ltd.	Sustained-release formulation for injection
WO2012063246A1 (en) *	2010-11-11	2012-05-18	Mapi Pharma Ltd.	Amorphous form of lurasidone hydrochloride
WO2012107890A2 (en) *	2011-02-10	2012-08-16	Ranbaxy Laboratories Limited	Crystalline forms of lurasidone hydrochloride
WO2012156981A1 (en)	2011-05-13	2012-11-22	Cadila Healthcare Limited	Pharmaceutical compositions of lurasidone
US8981095B2 (en)	2011-07-28	2015-03-17	Mapi Pharma Ltd.	Intermediate compounds and process for the preparation of lurasidone and salts thereof
CN102911169B (zh) *	2011-08-02	2015-05-06	上海医药工业研究院	一种卢拉西酮的制备方法
US20140243383A1 (en)	2011-08-24	2014-08-28	Cadila Healthcare Limited	Pharmaceutical compositions of silodosin
CN103446071B (zh) *	2012-05-29	2017-12-19	江苏豪森药业集团有限公司	一种口服片剂及其制备方法和用途
CN102688209A (zh) *	2012-06-21	2012-09-26	李兴惠	鲁拉西酮片和制备方法
CN102688210A (zh) *	2012-06-21	2012-09-26	李兴惠	鲁拉西酮的药物组合物和制备方法
CN106074414B (zh) *	2012-07-12	2019-01-18	成都康弘药业集团股份有限公司	一种含有鲁拉西酮的口腔崩解片及其制备方法
CN103006661B (zh) *	2012-12-06	2015-02-18	江苏先声药物研究有限公司	一种含有盐酸鲁拉西酮的制剂及其制备方法
US20150157628A1 (en) *	2013-12-11	2015-06-11	Saravanan Kannusamy	Pharmaceutical compositions of Lurasidone and Process for preparation thereof
WO2016012898A1 (en) *	2014-07-25	2016-01-28	Lupin Limited	Oral pharmaceutical composition of lurasidone
CN104606133A (zh) *	2015-01-07	2015-05-13	万特制药(海南)有限公司	鲁拉西酮口服混悬液及其制备方法
WO2016139683A2 (en) *	2015-03-05	2016-09-09	Jubilant Generics Limited	Pharmaceutical compositions of lurasidone and process for preparing the same
DE102016205950A1 (de) *	2016-04-08	2017-10-12	Dietrich Seidel	Mittel zur Verwendung bei entzündlichen Zuständen der Schleimhäute
EP3318279A1 (de) *	2016-11-02	2018-05-09	Sanovel Ilac Sanayi ve Ticaret A.S.	Feste orale pharmazeutische zusammensetzungen von lurasidon-hydrochlorid
CN108567758A (zh) *	2017-03-08	2018-09-25	湖南洞庭药业股份有限公司	盐酸鲁拉西酮片剂及其制备方法
CN107875122A (zh) *	2017-12-17	2018-04-06	佛山市弘泰药物研发有限公司	一种盐酸鲁拉西酮自微乳制剂及其制备方法
CN107854445A (zh) *	2017-12-17	2018-03-30	佛山市弘泰药物研发有限公司	一种盐酸鲁拉西酮分散片及其制备方法
CN107854446A (zh) *	2017-12-19	2018-03-30	佛山市弘泰药物研发有限公司	一种盐酸鲁拉西酮口崩片及其制备方法
EP3760206A4 (de)	2018-02-28	2021-11-03	Sumitomo Dainippon Pharma Co., Ltd.	Wässriges suspensionsartiges pharmazeutisches präparat mit kontrollierter auflösung
EP3772992B1 (de)	2018-04-10	2022-05-18	Freshfoodz GmbH	Verfahren zur konservierung einer warmzubereiteten speise und zum bereitstellen von gemeinschaftsverpflegung
JP2021518422A (ja) *	2018-04-13	2021-08-02	サムヤンバイオファーマシューティカルズコーポレイションＳａｍｙａｎｇＢｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓＣｏｒｐｏｒａｔｉｏｎ	レナリドミドを含む医薬組成物
CN115843243A (zh) *	2020-08-26	2023-03-24	浙江华海药业股份有限公司	盐酸鲁拉西酮组合物及其制备方法
AT17300U3 (de) *	2020-12-03	2022-02-15	G L Pharma Gmbh	Feste orale pharmazeutische Zusammensetzung
CN116615184A (zh)	2020-12-23	2023-08-18	住友制药株式会社	口服固体制剂

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4600579A (en) *	1983-06-07	1986-07-15	Mallinckrodt, Inc.	N-acetyl-p-aminophenol compositions containing partially gelatinized starch and method for preparing same
US4551177A (en)	1984-04-23	1985-11-05	National Starch And Chemical Corporation	Compressible starches as binders for tablets or capsules
US4609675A (en)	1984-08-17	1986-09-02	The Upjohn Company	Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US4837031A (en)	1987-09-17	1989-06-06	Mallinckrodt, Inc.	Compositions containing ibuprofen
US5047246A (en)	1988-09-09	1991-09-10	Bristol-Myers Company	Direct compression cyclophosphamide tablet
US4911921A (en)	1989-02-02	1990-03-27	Mallinckrodt, Inc.	High ibuprofen content granulations
US5104648A (en)	1989-02-02	1992-04-14	Mallinckrodt Specialty Chemicals Company	High ibuprofen content granulations
JP2800953B2 (ja)	1990-07-06	1998-09-21	住友製薬株式会社	新規なイミド誘導体
US5605889A (en)	1994-04-29	1997-02-25	Pfizer Inc.	Method of administering azithromycin
MX9706449A (es)	1995-02-28	1997-11-29	Hoechst Marion Roussel Inc	Composicion farmaceutica para compuestos de piperidinalcanol.
JP4022269B2 (ja) *	1995-05-26	2007-12-12	協和醗酵工業株式会社	医薬組成物
BR9814090A (pt)	1997-10-20	2000-10-03	Dainippon Pharmaceutical Co	Composição de drogas rapidamente solúvel
JP4063386B2 (ja)	1998-01-29	2008-03-19	キッセイ薬品工業株式会社	速放性経口医薬品組成物
US6150366A (en)	1998-06-15	2000-11-21	Pfizer Inc.	Ziprasidone formulations
EP1169024B1 (de) *	1999-03-31	2005-12-21	Janssen Pharmaceutica N.V.	Vorgelatinierte stärke in einer formulierung mit gesteuerter freigabe
US6586617B1 (en)	1999-04-28	2003-07-01	Sumitomo Chemical Takeda Agro Company, Limited	Sulfonamide derivatives
AU2001246861A1 (en) *	2000-04-10	2001-10-23	Sumitomo Pharmaceuticals Co. Ltd.	Sustained release preparations
DE60138722D1 (de) *	2000-09-22	2009-06-25	Dainippon Sumitomo Pharma Co	Orale zubereitungen mit vorteilhaften zerfallseigenschaften
JP4250423B2 (ja)	2001-03-19	2009-04-08	大日本住友製薬株式会社	アリール置換脂環式化合物及びそれを含有する医薬組成物
GB0209265D0 (en)	2002-04-23	2002-06-05	Novartis Ag	Organic compounds
EP2295061A1 (de) *	2002-08-22	2011-03-16	Dainippon Sumitomo Pharma Co., Ltd.	Verbindung zur Behanlung von Schizophrenie
JP2006514687A (ja)	2002-08-30	2006-05-11	ファルマシアコーポレイション	再現性のある医薬放出特性を示す医薬固形投与形態
JPWO2004078173A1 (ja) *	2003-02-05	2006-06-08	塩野義製薬株式会社	溶出性の改善された錠剤
DK3260117T3 (da)	2003-09-12	2019-07-01	Amgen Inc	Hurtigt opløsende formulering, der omfatter cinacalcet-hcl
JP4740740B2 (ja)	2003-12-09	2011-08-03	大日本住友製薬株式会社	薬物含有粒子および該粒子を含む固形製剤
WO2006096439A2 (en)	2005-03-04	2006-09-14	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
BRPI0611409B8 (pt)	2005-05-26	2021-05-25	Dainippon Sumitomo Pharma Co	preparação oral compreendendo lurasidona

2006
- 2006-05-26 BR BRPI0611409A patent/BRPI0611409B8/pt active IP Right Grant
- 2006-05-26 EP EP20110181100 patent/EP2422783B1/de active Active
- 2006-05-26 DK DK06746900.7T patent/DK1884242T3/da active
- 2006-05-26 CA CA2606510A patent/CA2606510C/en active Active
- 2006-05-26 US US11/919,678 patent/US8729085B2/en active Active
- 2006-05-26 SI SI200631567T patent/SI1884242T1/sl unknown
- 2006-05-26 MX MX2007014872A patent/MX2007014872A/es active IP Right Grant
- 2006-05-26 ES ES06746900T patent/ES2408687T3/es active Active
- 2006-05-26 RU RU2007148997A patent/RU2398586C3/ru not_active Application Discontinuation
- 2006-05-26 AU AU2006250340A patent/AU2006250340C1/en active Active
- 2006-05-26 WO PCT/JP2006/310571 patent/WO2006126681A1/ja active Application Filing
- 2006-05-26 PT PT67469007T patent/PT1884242E/pt unknown
- 2006-05-26 EP EP06746900.7A patent/EP1884242B1/de active Active
- 2006-05-26 CN CN2010105647842A patent/CN102048734B/zh not_active Expired - Fee Related
- 2006-05-26 ES ES11181100.6T patent/ES2535478T3/es active Active
- 2006-05-26 JP JP2007517921A patent/JP4733120B2/ja active Active
- 2006-05-26 KR KR1020137027051A patent/KR101552033B1/ko active IP Right Grant
- 2006-05-26 BR BR122020005056-0A patent/BR122020005056B1/pt active IP Right Grant
- 2006-05-26 KR KR1020077027270A patent/KR101380088B1/ko active IP Right Grant
- 2006-05-26 CN CN2006800182234A patent/CN101184489B/zh not_active Expired - Fee Related
- 2006-05-26 DK DK11181100.6T patent/DK2422783T3/en active
- 2006-05-26 PL PL06746900T patent/PL1884242T3/pl unknown
2008
- 2008-03-03 HK HK08102367.3A patent/HK1108379A1/xx unknown
2011
- 2011-03-18 JP JP2011061211A patent/JP5285105B2/ja active Active
2013
- 2013-05-14 CY CY20131100384T patent/CY1114118T1/el unknown
2014
- 2014-02-18 US US14/183,283 patent/US8883794B2/en active Active
- 2014-09-15 HU HUS1400051C patent/HUS1400051I1/hu unknown
- 2014-09-16 NL NL300690C patent/NL300690I2/nl unknown
- 2014-09-16 FR FR14C0069C patent/FR14C0069I2/fr active Active
- 2014-09-18 CY CY2014039C patent/CY2014039I2/el unknown
- 2014-09-18 LU LU92550C patent/LU92550I2/xx unknown
- 2014-10-10 US US14/512,189 patent/US9555027B2/en active Active
2015
- 2015-06-08 US US14/733,204 patent/US9907794B2/en active Active
2018
- 2018-02-06 US US15/889,893 patent/US20180161322A1/en not_active Abandoned

Also Published As

Publication number	Publication date
SI1884242T1 (sl)	2013-07-31
LU92550I2 (fr)	2015-11-02
CA2606510A1 (en)	2006-11-30
MX2007014872A (es)	2008-02-15
KR20130122019A (ko)	2013-11-06
BRPI0611409A8 (pt)	2015-12-15
PT1884242E (pt)	2013-05-21
CA2606510C (en)	2014-07-22
CN102048734B (zh)	2013-11-20
CN101184489B (zh)	2011-01-19
US20090143404A1 (en)	2009-06-04
RU2398586C3 (ru)	2017-10-04
HK1108379A1 (en)	2008-05-09
US8883794B2 (en)	2014-11-11
JPWO2006126681A1 (ja)	2008-12-25
DK2422783T3 (en)	2015-05-11
US20150056284A1 (en)	2015-02-26
US8729085B2 (en)	2014-05-20
US20150265611A1 (en)	2015-09-24
CY2014039I1 (el)	2016-06-22
CY2014039I2 (el)	2016-06-22
EP1884242A4 (de)	2009-07-01
RU2398586C2 (ru)	2010-09-10
CN102048734A (zh)	2011-05-11
KR101552033B1 (ko)	2015-09-09
ES2408687T3 (es)	2013-06-21
WO2006126681A1 (ja)	2006-11-30
JP2011126915A (ja)	2011-06-30
AU2006250340B2 (en)	2012-02-09
BR122020005056A2 (de)	2010-11-23
AU2006250340C1 (en)	2014-06-12
CY1114118T1 (el)	2016-06-22
AU2006250340A1 (en)	2006-11-30
HUS1400051I1 (hu)	2016-10-28
FR14C0069I1 (fr)	2014-10-24
US20140235651A1 (en)	2014-08-21
EP1884242B1 (de)	2013-04-17
KR20080012306A (ko)	2008-02-11
JP4733120B2 (ja)	2011-07-27
US9907794B2 (en)	2018-03-06
US20180161322A1 (en)	2018-06-14
BR122020005056A8 (pt)	2022-11-22
RU2007148997A (ru)	2009-07-10
ES2535478T3 (es)	2015-05-12
DK1884242T3 (da)	2013-05-06
EP2422783A1 (de)	2012-02-29
EP1884242A1 (de)	2008-02-06
BRPI0611409A2 (pt)	2010-11-23
NL300690I2 (nl)	2017-11-02
EP2422783B1 (de)	2015-04-08
PL1884242T3 (pl)	2013-09-30
BRPI0611409B1 (pt)	2020-12-29
JP5285105B2 (ja)	2013-09-11
BRPI0611409B8 (pt)	2021-05-25
US9555027B2 (en)	2017-01-31
KR101380088B1 (ko)	2014-04-10
CN101184489A (zh)	2008-05-21
BR122020005056B1 (pt)	2023-01-10

Publication	Publication Date	Title
FR14C0069I2 (fr)	2015-11-20	Composition pharmaceutique comprenant le lurasidone
DK1962873T3 (da)	2013-08-26	Farmaceutiske sammensætninger omfattende oxalat-reducerende bakterier
ITBO20050123A1 (it)	2005-06-06	Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
BRPI0511900A (pt)	2008-01-22	composições farmacêuticas
NO20075628L (no)	2007-11-05	Farmasøytiske formuleringer
DK1940467T3 (da)	2017-02-13	Lægemiddelsammensætning med langvarig frigivelse
DK1957073T3 (da)	2014-05-12	Lægemiddel
DK1725218T3 (da)	2014-09-01	Farmaceutisk sammensætning omfattende pimobendan
NL1029431A1 (nl)	2006-01-09	Vloeibare pesticidesamenstellingen.
BRPI0715712A2 (pt)	2014-06-24	Composição farmacêutica
BRPI0614205A2 (pt)	2016-11-22	composto, composição farmacêutica, e, uso de composto
FR18C1032I2 (fr)	2019-08-09	Anticorps anti-fgf23 et composition pharmaceutique le comprenant
FR2881643B1 (fr)	2008-12-05	Composition matifiante comprenant de la perlite
BRPI0719398A2 (pt)	2015-03-31	Composição farmacêutica.
BRPI0719393A2 (pt)	2015-03-31	Composição farmacêutica
ATE453384T1 (de)	2010-01-15	Neue dosierformulierung
DK3072507T3 (da)	2021-02-08	Farmaceutiske sammensætninger til glukokortikoidsubstitutionsterapi
BRPI0716445A2 (pt)	2013-09-17	composiÇço farmacÊutica
DK1741339T3 (da)	2014-05-12	Pesticid sammensætning
BRPI0720234A2 (pt)	2013-12-24	Composição farmacêutica
DK1587478T3 (da)	2013-10-21	Farmaceutisk sammensætning
DE602006000877D1 (de)	2008-05-21	Emulsionszusammensetzung
BRPI0615630A2 (pt)	2016-11-16	composição farmacêutica, e, uso de sertindol
MA28603B1 (fr)	2007-05-02	Composition pharmaceutique antimycobacterienne
BRPI0614413A2 (pt)	2016-11-22	composto, e, composição farmacêutica